|
Volumn 338, Issue 6113, 2012, Pages 1431-1432
|
A genetic intervention stands a skip away from clinical tests
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTISENSE OLIGONUCLEOTIDE;
DANTROLENE;
DYSTROPHIN;
MESSENGER RNA PRECURSOR;
RYANODINE RECEPTOR;
CALCIUM CHANNEL BLOCKING AGENT;
CENTRAL MUSCLE RELAXANT;
RNA PRECURSOR;
DISEASE SEVERITY;
DRUG;
GENETIC ANALYSIS;
MUSCLE;
PROTEIN;
RODENT;
ANTISENSE THERAPY;
CALCIUM SIGNALING;
CLINICAL TRIAL (TOPIC);
DISEASE SEVERITY;
DRUG SCREENING;
DUCHENNE MUSCULAR DYSTROPHY;
EXON SKIPPING;
GENE MUTATION;
GENETIC ASSOCIATION;
GENETIC CODE;
HUMAN;
IMMUNOFLUORESCENCE;
NONHUMAN;
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROTEIN SYNTHESIS;
RNA SPLICING;
SHORT SURVEY;
UPREGULATION;
ANIMAL;
ARTICLE;
BIOSYNTHESIS;
DISEASE MODEL;
EXON;
GENE DELETION;
GENETICS;
METABOLISM;
MOUSE;
ANIMALS;
CALCIUM CHANNEL BLOCKERS;
CLINICAL TRIALS AS TOPIC;
DANTROLENE;
DISEASE MODELS, ANIMAL;
DYSTROPHIN;
EXONS;
MICE;
MUSCLE RELAXANTS, CENTRAL;
MUSCULAR DYSTROPHY, DUCHENNE;
OLIGONUCLEOTIDES, ANTISENSE;
RNA PRECURSORS;
RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;
SEQUENCE DELETION;
|
EID: 84871033293
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.1233074 Document Type: Short Survey |
Times cited : (2)
|
References (15)
|